
Initiator Pharma to present at Redeye Healthcare Day 2026

Initiator Pharma A/S, a clinical-stage biotech company, today announces that its CEO, Claus Elsborg Olesen, will present the latest developments at the Redeye Healthcare Day 2026, Wednesday April 14, at 09:20.

Tune in for the live broadcast at:

<https://www.redeye.se/events/1145882/redeye-healthcare-day-2026>

The presentation will also be accessible on www.redeye.se

For additional information about Initiator Pharma, please contact:

Claus Elsborg Olesen, CEO
Telephone: +45 6126 0035
E-mail: ceo@initiatorpharma.com

About Initiator Pharma

Initiator Pharma A/S is a Danish clinical stage emerging pharma company developing innovative drugs that target key unmet medical needs within the central and peripheral nervous system. Initiator Pharma's pipeline consists of two clinical stage assets – pudafensine and IP2018 – and one preclinical asset. With pudafensine the company has reported positive, statistically significant and clinically relevant efficacy data in a Phase IIb clinical trial with patients suffering from ED. With IP2018 the company has reported positive, statistically significant, and dose-dependent clinical observations related to efficacy in psychogenic erectile dysfunction (ED) in a Phase IIa clinical trial of IP2018 in patients with mild to moderate ED.

Initiator Pharma is listed on Nasdaq First North Growth Market (ticker: INIT). Redeye Sweden AB is the company's Certified Adviser. For more information, please visit www.initiatorpharma.com.

Attachments

Initiator Pharma to present at Redeye Healthcare Day 2026